Scholarlink

Background <p>Appendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. <i>KRAS</i> is the most commonly mutated gene in AA and a promising therapeutic target, but its preclinical and translational relevance in AA remains unclear.</p> Methods <p>We evaluated KRAS<sup>G12D</sup>–specific (MRTX1133) and pan-KRAS inhibitor (RMC-6236) in <i>KRAS</i><sup><i>mut</i></sup> organoid and PDX models of AA. Tumor-intrinsic and microenvironmental responses were characterized using multi-omics profiling. Clinical outcomes were also assessed in cohort of 15 patients with AA treated with KRAS inhibitors.</p> Results <p>MRTX1133 was highly effective for KRAS<sup>G12D</sup> organoids (IC50 = 4.1 nM); both KRAS<sup>G12D</sup> and KRAS<sup>G12V</sup> organoids were sensitive to RMC-6236 (IC50 = 4.4 nM vs. 0.5 nM, respectively). In PDX models of peritoneal carcinomatosis from AA, MRTX1133 reduced tumor growth in the KRAS<sup>G12D</sup> model TM00351, and RMC-6236 reduced tumor growth in KRAS<sup>G12V</sup> model AAPDX-16. Pathologic evaluation showed dramatically reduced tumor cellularity, proliferation, and pERK expression as well as induction of apoptosis. Gene Set Enrichment Analysis (GSEA) demonstrated consistent downregulation of E2F targets and RAS/ERK signaling across both models, confirming on-target KRAS inhibition, alongside upregulation of EMT (Epithelial-to-Mesenchymal Transition), suggesting a shared resistance-associated transcriptional program. Interferon-alpha and interferon-gamma signaling were significantly upregulated following pan-KRAS inhibition, implicating TME (Tumor Microenvironment) immunomodulation as a downstream consequence of KRAS inhibition in AA. scRNA-seq analysis of the TME showed a dramatic shift from normal to inflammatory cancer-associated fibroblasts (CAFs) following KRAS inhibition. Upregulation of interferon alpha and gamma pathways was also observed, suggesting that KRAS inhibition can activate innate immune response in the setting of peritoneal metastases. Among 15 patients treated with KRAS inhibitors (8 G12D, 5 G12C, 2 pan-KRAS), all evaluable pateints had a biochemical response by serum markers and clinical benefit by imaging criteria (1 CR, 1 PR, 12 SD).</p> Conclusions <p>While effective suppression of RAS/ERK signaling by KRAS inhibitors reduces tumor growth, adaptive activation of EMT pathway may mediate resistance in <i>KRAS</i><sup><i>mut</i></sup> AA. Additionally, KRAS inhibition remodels TME and may enhance innate immune signaling. These findings support the continued clinical development of KRAS inhibitors in AA and provide a rationale for combination strategies targeting resistance pathways and stromal remodeling.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Saikat Chowdhury,
  • Ichiaki Ito,
  • Vinay K. Pattalachinti,
  • Abdelrahman M. G. Yousef,
  • Mahmoud M. G. Yousef,
  • Sacha El Khoury,
  • Nicholas Hornstein,
  • Ashlee Nichole Seldomridge,
  • David Hong,
  • Micheal J. Overman,
  • Melissa W. Taggart,
  • Wai Chin Foo,
  • Beth Helmink,
  • Keith F. Fournier,
  • John Paul Shen

摘要

Background

Appendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. KRAS is the most commonly mutated gene in AA and a promising therapeutic target, but its preclinical and translational relevance in AA remains unclear.

Methods

We evaluated KRASG12D–specific (MRTX1133) and pan-KRAS inhibitor (RMC-6236) in KRASmut organoid and PDX models of AA. Tumor-intrinsic and microenvironmental responses were characterized using multi-omics profiling. Clinical outcomes were also assessed in cohort of 15 patients with AA treated with KRAS inhibitors.

Results

MRTX1133 was highly effective for KRASG12D organoids (IC50 = 4.1 nM); both KRASG12D and KRASG12V organoids were sensitive to RMC-6236 (IC50 = 4.4 nM vs. 0.5 nM, respectively). In PDX models of peritoneal carcinomatosis from AA, MRTX1133 reduced tumor growth in the KRASG12D model TM00351, and RMC-6236 reduced tumor growth in KRASG12V model AAPDX-16. Pathologic evaluation showed dramatically reduced tumor cellularity, proliferation, and pERK expression as well as induction of apoptosis. Gene Set Enrichment Analysis (GSEA) demonstrated consistent downregulation of E2F targets and RAS/ERK signaling across both models, confirming on-target KRAS inhibition, alongside upregulation of EMT (Epithelial-to-Mesenchymal Transition), suggesting a shared resistance-associated transcriptional program. Interferon-alpha and interferon-gamma signaling were significantly upregulated following pan-KRAS inhibition, implicating TME (Tumor Microenvironment) immunomodulation as a downstream consequence of KRAS inhibition in AA. scRNA-seq analysis of the TME showed a dramatic shift from normal to inflammatory cancer-associated fibroblasts (CAFs) following KRAS inhibition. Upregulation of interferon alpha and gamma pathways was also observed, suggesting that KRAS inhibition can activate innate immune response in the setting of peritoneal metastases. Among 15 patients treated with KRAS inhibitors (8 G12D, 5 G12C, 2 pan-KRAS), all evaluable pateints had a biochemical response by serum markers and clinical benefit by imaging criteria (1 CR, 1 PR, 12 SD).

Conclusions

While effective suppression of RAS/ERK signaling by KRAS inhibitors reduces tumor growth, adaptive activation of EMT pathway may mediate resistance in KRASmut AA. Additionally, KRAS inhibition remodels TME and may enhance innate immune signaling. These findings support the continued clinical development of KRAS inhibitors in AA and provide a rationale for combination strategies targeting resistance pathways and stromal remodeling.